Live
Lupin has received final approval for marketing generic Aricept tablets that are used in treatment of dementia from the US drug regulator.
It said in a statement that the company’s US subsidiary, Lupin Pharmaceuticals would commence promoting the product shortly in the US.
It further added that “…it has received final approval for its Donepezil Hydrochloride Tablets, 23 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eisai Inc’s Aricept tablets.”
